Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus FLUORODOPA F18.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus FLUORODOPA F18.
CIS-MDP vs FLUORODOPA F18
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Fluorodopa F18 is a radioactive diagnostic agent that is taken up by dopaminergic neurons in the striatum and converted by aromatic L-amino acid decarboxylase to fluorodopamine, which is stored in presynaptic vesicles. The emitted positrons allow for PET imaging to assess functional integrity of the nigrostriatal dopaminergic system.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
185-370 MBq (5-10 mCi) intravenous bolus injection for positron emission tomography imaging. Administered once per imaging session.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
110 minutes (physical half-life of F-18); biological half-life is approximately 2-3 hours, allowing imaging up to 4-6 hours post-injection.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Primarily renal excretion; approximately 70-80% of the injected dose is excreted unchanged in urine within 2 hours, with the remainder eliminated via biliary/fecal routes (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical